Twist Bioscience Stock Price, News & Analysis

Twist Bioscience (NASDAQ: TWST) has appointed Trynka Shineman Blake to its board of directors and audit committee. Ms. Shineman Blake, former CEO of Vistaprint, brings nearly three decades of experience in corporate governance, customer experience, digital transformation, and global marketing.

During her tenure at Vistaprint, she played a crucial role in scaling the business from under $100 million to over $1 billion in revenue. Her appointment comes at a strategic time as Twist advances toward adjusted EBITDA breakeven while maintaining focus on innovative solutions.

Twist Bioscience (NASDAQ: TWST) has announced its financial results for the third quarter of fiscal 2025, ended June 30, 2025. CEO Emily M. Leproust highlighted the company's strong balance sheet and disciplined cost management approach that supports their business execution.

The company will host a conference call and webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the quarterly results. Interested participants must pre-register through the company's website to receive dial-in details.

Twist Bioscience (NASDAQ: TWST) has launched a new humanized transgenic (HuTg) mouse model to enhance its antibody discovery services. The new model offers a fee-for-service approach, eliminating the need for traditional licensing negotiations with providers.

The HuTg platform can be integrated with Twist's existing DiversimAb mouse model and B cell screening platforms, enabling researchers to generate human antibody candidates more efficiently. The technology accelerates lead discovery and optimization, reducing the timeline from months to weeks for identifying fully human hits.

Twist Bioscience (NASDAQ: TWST) has announced the granting of inducement equity awards to 36 newly hired employees. The awards total 70,254 equity units, comprising 56,182 restricted stock units (RSUs) and up to 14,072 performance stock units (PSUs).

The RSUs feature two vesting schedules over 48 months: one with 25% vesting after the first year followed by quarterly vesting, and another with straight quarterly vesting. The PSUs can be earned at 50%-140% of target based on performance metrics, with vesting through fiscal year 2027. These awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Twist Bioscience (NASDAQ: TWST) has scheduled its fiscal 2025 third quarter financial results announcement for August 4, 2025, before market opening. The company will host a conference call and live audio webcast at 8:00 AM Eastern Time to discuss the results and provide business updates.

Interested participants can access the financial results through the Investor Relations section of Twist's website. Those wishing to join via telephone must pre-register through the company's IR website to receive dial-in details and a unique PIN. The webcast replay will be available for two weeks following the call.

Twist Bioscience (NASDAQ: TWST) has announced an expansion of its Express delivery service for all Gene Fragments, offering turnaround times starting at two business days regardless of configuration. The company now provides Gene Fragments at prices starting from seven cents per base pair with no hidden fees, applicable to all configurations including both adapters-off and adapters-on formats.

The enhanced service includes flexible delivery formats such as tubes, plates, normalization, and resuspension. Notably, Twist will now offer gene fragments without adaptors as a standard offering, removing previously charged adaptor removal fees. The company maintains an industry-leading error rate of 1:7500, supporting various applications including protein engineering, antibody discovery, and diagnostic assays.

Twist Bioscience (NASDAQ: TWST) and Element Biosciences have expanded their collaboration to develop comprehensive next-generation sequencing (NGS) solutions. Under the partnership, Twist will become the exclusive provider of new Trinity™ library prep and target enrichment kits for Element's AVITI™ sequencer. The collaboration builds on their existing relationship, which has already produced Element-native kits and 1-hour fast hybridization Trinity solutions. The partnership aims to streamline hybrid capture processes and will focus on serving markets including agbio, population genomics, and clinical research. The integrated solution combines Element's Trinity workflow with Twist's library preparation capabilities, offering researchers access to end-to-end workflows from library prep through sequencing on Element's AVITI platform. Both companies will engage in joint commercial activities to improve customer access to these solutions.

Twist Bioscience (NASDAQ: TWST), a life sciences company, announced that its President and COO Patrick Finn, Ph.D. will present at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for June 3, 2025, at 10:00 am Central Time in Chicago, Illinois. Investors can access the live webcast through the company's investor relations website's "Investor Calendar" page. A replay will be available for 30 days following the event.

Twist Bioscience (NASDAQ: TWST) has announced the granting of inducement equity awards to 36 new employees. The awards include 53,600 restricted stock units (RSUs) and up to 19,379 performance stock units (PSUs). The RSUs have two vesting schedules over 48 months: one with 25% vesting after the first year and 1/16 quarterly thereafter, and another with straight 1/16 quarterly vesting. The PSUs will vest based on performance metrics set by the Board's Compensation Committee, with potential earnings of 50%-140% of target by fiscal year 2027. These grants were made under Twist's Amended and Restated Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).